PhD-student (ESR1): tumour-selective PD-1/PD-L1 immunotherapy and drug delivery

Universitair Medisch Centrum Groningen

Universitair Medisch Centrum Groningen

Functiegebied:
PhD student
Regio:
Groningen
Standplaats:
Regio Groningen
Aanstelling:
Tijdelijke aanstelling
Dienstverband:
Niet nader bepaald
Plaatsingsdatum:
31-1-2019

Vacatureomschrijving

Working environment

The PhD candidate will be working as part of an international consortium on their search for an immunotherapeutic approach to cancer treatment and will start their 3 year research project at the University Medical Center Groningen (UMCG) / Netherlands, one of the leading academic centers of the Netherlands. At the UMCG, new PD-1 checkpoint targeting immunotherapeutic will be developed and preclinically evaluated. After 18 months, the candidate will continue in Prague / Czech Republic at the nanobiotechnology company Inocure SRO. Inocure is a leading company in drug formulation and in in vitro modelling and the candidate will exploit this expertise for further development of PD-1 checkpoint immunotherapeutics. With this project, the candidate will acquire experience in both industrial and academic research.

This project is part of a collaborative training network of 10 closely related projects (www.i-direct-itn.eu) in which PhD students will benefit from networking opportunities. This includes a multidisciplinary training programme with network-wide training events that will be provided to the candidates. Herewith, the PhD project will provide the candidate a unique opportunity to obtain knowledge/expertise on important facets of both academia and industry.

Job description

Development and preclinical validation of tumour-selective PD-1/PD-L1 immunotherapeutics and drug delivery systems
This PhD student position offers an exciting and innovative research project aimed at further development of targeting of the PD-1/PD-L1 immune checkpoint for cancer immunotherapy. In brief, a novel bispecific antibody-based approach that selectively removes this important checkpoint at the site of the cancer will be developed. Further, the immunotherapeutic will be formulated in state-of-the-art Drug Delivery Systems (DDS) to ensure timely and tumor-localized release of bioactive drug. This approach will be tested in in-house developed model systems for tumor-selective binding and functional immunomodulatory activity. This research project will end with a PhD thesis defense at the University of Groningen.

Keywords: checkpoint targeting, bispecific antibody, nanoparticles, surface modification, drug-delivery

Key Responsibilities
  • Preparation of tumour-targeted bsAbs & immunocytokines
  • Nanoparticle-based drug-delivery formulation
  • Primary patient-derived cell culturing
  • Development of 3D model of tumor micro-environment
  • Various encapsulation and surface modification activities
  • Optimization of the in vitro test conditions for a realistic simulation of the in vivo conditions
  • Management, presentation and publication of research data

What do we need

  • You are in the first four years of your research career and does not have a doctoral degree
  • Residence duration in the Netherlands does not exceed 12 months in total within the last 3 years
  • MSc in biology, biochemistry, biotechnology, engineering or related
  • Collaboration skills, demonstrating agility and initiative. Ability to communicate effectively in English

The UMCG has a preventive Hepatitis B policy. The UMCG can provide you with the vaccination, should it be required for your position.

In case of specific professions a ‘Certificate of Good Conduct’ is required.

What do we offer

A PhD student position for 3 years as part of a Marie Curie Actions Innovative Industrial Doctorate training network. 1st Hosting institution: Location: UMCG, Groningen, The Netherlands, duration: 18 months. 2nd Hosting institution: Location: InoCure, Prague, Czech Republic , duration: 18 months. Intended start date: April 2019. Benefits according to EU MCA regulations.

Applying for a job
Please send your application to i-direct@onco.umcg.nl as job application ESR1 PD-1/PD-L1 immunotherapy. The application deadline is 28 February 2019.
(please do not use the digital application form)

Applying for a job




Meer vacatures in de zorg bekijken?

Direct de laatste relevante vacatures in uw mailbox ontvangen?

Vacature alerts